NCT02196181 2026-03-18
Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
27 trialsNCT02231775 2026-02-13
Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02910700 2025-12-17
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01972347 2025-12-16
Neo Combi
Melanoma Institute Australia
Phase 2 Active not recruiting
NCT04310397 2024-10-30
Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04059224 2023-09-26
TraMel-WT
Universitair Ziekenhuis Brussel
Phase 2 Completed
NCT05299580 2023-09-14
"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"
Fondazione Melanoma Onlus
Phase 2 Withdrawn
NCT02858921 2023-08-30
Neo Trio
Melanoma Institute Australia
Phase 2 Unknown
NCT03563729 2023-07-13
MEMBRAINS
Herlev Hospital
Phase 2 Recruiting
NCT02052193 2022-12-19
Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study
University Hospital Tuebingen
Phase 2 Terminated
NCT02083354 2022-02-01
Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma
Novartis
Phase 2 Completed
NCT02974803 2021-08-20
Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases
Canadian Cancer Trials Group
Phase 2 Terminated
NCT03352947 2020-12-08
INTERIM
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Completed
NCT03972046 2020-10-19
Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma
TriHealth Inc.
Phase 2 Withdrawn
NCT02410863 2020-10-14
BOTTOM
University Hospital, Essen
Phase 2 Terminated
NCT01682213 2020-05-26
Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01072175 2019-07-05
Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212
Novartis
Phase 2 Completed
NCT02039947 2019-05-21
Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
Novartis
Phase 2 Completed
NCT02314143 2019-02-18
Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib
GlaxoSmithKline
Phase 2 Terminated
NCT02296996 2019-01-23
Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients
Universitair Ziekenhuis Brussel
Phase 2 Completed
NCT01978236 2018-08-17
Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites
GlaxoSmithKline
Phase 2 Terminated
NCT01721603 2018-01-23
Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets
University of California, San Francisco
Phase 2 Terminated
NCT01153763 2017-09-27
A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
GlaxoSmithKline
Phase 2 Completed
NCT02625337 2017-09-15
IMPemBra
The Netherlands Cancer Institute
Phase 2 Unknown
NCT01928940 2017-07-24
Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)
GlaxoSmithKline
Phase 2 Completed
NCT01701037 2017-06-23
Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT01619774 2016-12-12
An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor
M.D. Anderson Cancer Center
Phase 2 Completed